Redbiotec specializes in developing high-quality vaccines to fight difficult diseases. After successfully spinning out the CMV vaccine program that was acquired by Pfizer, Redbiotec is currently developing HSV-2 therapeutic vaccine (immunotherapy).

HSV-2 immunotherapy program

  • Therapeutic subunit vaccines, our lead candidate being RBT-3
  • T-cell-mediated protection
  • Best-in-class antigens by engineering
  • Strong preclinical data: Redbiotec leads show 90% reduction of lesion score (nearly double that of GEN-003 from competitor’s program)
  • Aimed at outperforming antivirals, and allowing patients to stay symptom-free for >12 months upon one-time vaccination

Potential of increasing antigen performance by

  • Optimization of epitope content
  • Evaluation of alternative adjuvant systems
  • Combination with other antigens

Patent status: pending

Select conference presentations

  • In vitro and in vivo Evaluation of Novel HSV-2 Recombination Antigens as Therapeutic Vaccine Candidates. Presented by Redbiotec during the 42nd Annual International Herpesvirus Workshop, July 29 – Aug 2, 2017
  • Novel HSV-2 Recombinant Antigens and their Evaluation as Vaccine Candidates. Presented by Redbiotec during the 41st Annual International Herpesvirus Workshop, July 23-27, 2016
Download Program Information